June 23, 2011 8:29 AM EDT Canaccord Genuity maintains a 'Buy' on...

June 23, 2011 8:29 AM EDT

Canaccord Genuity maintains a 'Buy' on Heartware Intl (NASDAQ: HTWR).

Canaccord analyst says, "HTWR released a favorable update on the thrombus issue that has weighed on the shares lately. Early data suggest that thrombus rates have decreased after more compliance to a 325mg aspirin regiment. Additional data is expected to be presented later this year. We remain bullish about LVAD growth potential both near- and long-term, and continue to believe HTWR will achieve #1 OUS share in H2/11 and #1 worldwide share by 2015. We would be buyers of HTWR at current levels."

For more ratings news on Heartware Intl click here and for the rating history of Heartware Intl click here.

Shares of Heartware Intl closed at $71.27 yesterday, with a 52 week range of $60.38-$99.10